Drug intelligence / Profile preview

lecozotan

Development stage: Phase 3
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

Lecozotan is a small molecule, investigational drug developed for the symptomatic treatment of cognitive deficits in Alzheimer's disease. It acts as a potent, selective, and silent antagonist of the serotonin 1A (5-hydroxytryptamine 1A or 5-HT1A) receptor. By blocking this receptor, lecozotan enhances potassium-stimulated release of acetylcholine and glutamate in the hippocampus—neurotransmitters crucial for cognitive function. This mechanism is believed to potentiate cholinergic and glutamatergic neurotransmission involved in learning and memory. Lecozotan was originally developed by Wyeth and reached Phase III clinical trials for Alzheimer's disease[1][2][3][4][5][6][7][8].

Brand names: Lecozotan SR
Other names: lecozotan hydrochloridelecozotan HCl

Targets

HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))

Beyond the preview

Go deeper on lecozotan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lecozotan.

Explore the full profile